K. Wildhagen

490 total citations
20 papers, 369 citations indexed

About

K. Wildhagen is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Physiology. According to data from OpenAlex, K. Wildhagen has authored 20 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 5 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Physiology. Recurrent topics in K. Wildhagen's work include Systemic Lupus Erythematosus Research (13 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). K. Wildhagen is often cited by papers focused on Systemic Lupus Erythematosus Research (13 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). K. Wildhagen collaborates with scholars based in Germany and Norway. K. Wildhagen's co-authors include Roald Omdal, Ragnar Gunnarsson, Thomas Folkmann Hansen, H. Deicher, Otmar Schober, H. Hundeshagen, Peter Heintz, Inger Marie Skoie, G.-J. Meyer and Henry G. Kunkel and has published in prestigious journals such as Neurology, Psychiatry Research and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

K. Wildhagen

18 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Wildhagen Germany 9 215 123 85 70 66 20 369
Hiroyuki Nara Japan 9 305 1.4× 91 0.7× 69 0.8× 158 2.3× 100 1.5× 23 519
M. Frigui Tunisia 12 202 0.9× 70 0.6× 42 0.5× 76 1.1× 35 0.5× 41 349
Dèlia Reina Spain 11 238 1.1× 64 0.5× 63 0.7× 84 1.2× 23 0.3× 53 427
Rolando Cimaz Italy 11 227 1.1× 56 0.5× 37 0.4× 62 0.9× 26 0.4× 19 363
Anthony G. DiBartolomeo United States 9 202 0.9× 90 0.7× 42 0.5× 36 0.5× 54 0.8× 16 401
PY Hatron France 13 133 0.6× 72 0.6× 42 0.5× 48 0.7× 74 1.1× 35 356
George F. Duna United States 9 259 1.2× 449 3.7× 193 2.3× 45 0.6× 108 1.6× 11 620
Eva H. Baart de la Faille-Kuyper Netherlands 7 101 0.5× 106 0.9× 21 0.2× 67 1.0× 49 0.7× 9 365
Müge Bıçakçıgil Türkiye 8 157 0.7× 131 1.1× 82 1.0× 95 1.4× 12 0.2× 11 379
Gregory Perry United Kingdom 10 146 0.7× 193 1.6× 25 0.3× 112 1.6× 15 0.2× 16 383

Countries citing papers authored by K. Wildhagen

Since Specialization
Citations

This map shows the geographic impact of K. Wildhagen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Wildhagen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Wildhagen more than expected).

Fields of papers citing papers by K. Wildhagen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Wildhagen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Wildhagen. The network helps show where K. Wildhagen may publish in the future.

Co-authorship network of co-authors of K. Wildhagen

This figure shows the co-authorship network connecting the top 25 collaborators of K. Wildhagen. A scholar is included among the top collaborators of K. Wildhagen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Wildhagen. K. Wildhagen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vikse, Jens, Kristín Jónsdóttir, Jan Terje Kvaløy, K. Wildhagen, & Roald Omdal. (2019). Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatology International. 39(6). 1083–1090. 23 indexed citations
2.
Vikse, Jens, et al.. (2019). Tubulointerstitiell nefritt og uveitt-syndrom. Tidsskrift for Den norske legeforening. 139(8). 1 indexed citations
3.
Skoie, Inger Marie, K. Wildhagen, & Roald Omdal. (2010). Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatology International. 32(4). 1049–1053. 28 indexed citations
4.
Stoppe, Gabriela, K. Wildhagen, Henry G. Kunkel, & H. Deicher. (2008). Zentralnervöse Beteiligung bei systemischem Lupus erythematodes. DMW - Deutsche Medizinische Wochenschrift. 115(11). 426–431.
5.
Gøransson, Lasse G., P Øgreid, Emiel A. M. Janssen, et al.. (2008). Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality. Scandinavian Journal of Rheumatology. 37(2). 130–134. 6 indexed citations
6.
Omdal, Roald, et al.. (2005). Anti‐CD20 therapy of treatment‐resistant Wegener's granulomatosis: favourable but temporary response. Scandinavian Journal of Rheumatology. 34(3). 229–232. 98 indexed citations
7.
Harboe, Erna, Lasse G. Gøransson, K. Wildhagen, & Roald Omdal. (2005). [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].. PubMed. 125(12). 1650–2. 2 indexed citations
8.
Omdal, Roald, Per M. Roos, K. Wildhagen, & Ragnar Gunnarsson. (2004). Respiratory arrest in systemic lupus erythematosus due to phrenic nerve neuropathy. Lupus. 13(10). 817–819. 10 indexed citations
9.
Sailer, Michael, Wolfgang Burchert, Ch. Ehrenheim, et al.. (1997). Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. Journal of Neurology. 244(3). 186–193. 51 indexed citations
10.
Runge, Martin, et al.. (1997). Detection of Ureaplasma urealyticum in urine of patients with systemic lupus erythematosus and healthy individuals by culture and polymerase chain reaction. Journal of Medical Microbiology. 46(5). 413–418. 5 indexed citations
11.
Wildhagen, K., et al.. (1993). Follow-up of Patients with Double Stranded DNA Antibodies Induced by Sutfasalazine during the Treatment of Inflammatory Rheumatic Diseases. Scandinavian Journal of Rheumatology. 22(6). 299–301. 11 indexed citations
12.
Wildhagen, K., K Hartung, Michael Hammer, et al.. (1993). Drug-related lupus in a patient with rheumatoid arthritis under sulfasalazine treatment. Clinical Rheumatology. 12(2). 265–267. 7 indexed citations
13.
Wildhagen, K., G.-J. Meyer, Otmar Schober, et al.. (1990). Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology. 40(2). 304–304. 75 indexed citations
14.
Wildhagen, K., et al.. (1990). [Imaging diagnosis of central nervous system involvement in panarteritis nodosa].. PubMed. 48(6). 323–5. 6 indexed citations
15.
Wildhagen, K., et al.. (1989). [Use of fluorodeoxyglucose PET in the diagnosis of central nervous system lupus erythematosus and a comparison with CT and MRI].. PubMed. 28(5). 187–92. 8 indexed citations
16.
Wildhagen, K., et al.. (1989). PET and MR imaging in a neuro-beh�et syndrome. European Journal of Nuclear Medicine and Molecular Imaging. 15(11). 764–766. 14 indexed citations
17.
18.
Wildhagen, K., et al.. (1989). Einsatz der FDG-PET bei der Diagnostik des zentralnervösen Lupus erythematodes und Vergleich mit CT und MRI. Nuklearmedizin - NuclearMedicine. 28(5). 187–192. 4 indexed citations
19.
Wildhagen, K., et al.. (1988). [Therapy of a hypereosinophilic syndrome with cardiac involvement].. PubMed. 77(1). 44–7. 1 indexed citations
20.
Wildhagen, K., et al.. (1987). Immunodeficiency Syndrome Associated with Aurothiomalate Treatment in a Patient with Rheumatoid Arthritis. Scandinavian Journal of Rheumatology. 16(3). 217–220. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyuki Nara Breakdown of academic impact, for papers by M. Frigui Breakdown of academic impact, for papers by Dèlia Reina Breakdown of academic impact, for papers by Rolando Cimaz Breakdown of academic impact, for papers by Anthony G. DiBartolomeo Breakdown of academic impact, for papers by PY Hatron Breakdown of academic impact, for papers by George F. Duna Breakdown of academic impact, for papers by Eva H. Baart de la Faille-Kuyper Breakdown of academic impact, for papers by Müge Bıçakçıgil Breakdown of academic impact, for papers by Gregory Perry
Rankless by CCL
2026